|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0032529,
umls-concept:C0035525,
umls-concept:C0521026,
umls-concept:C0524910,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1425475,
umls-concept:C1521761,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-18
|
|
pubmed:abstractText |
Pegylated interferon and ribavirin (PEG-IFN/RBV) therapy for chronic hepatitis C virus (HCV) genotype 1 infection is effective in 50% of patients. Recent studies revealed an association between the IL28B genotype and treatment response. We aimed to develop a model for the pre-treatment prediction of response using host and viral factors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0168-8278
|
|
pubmed:author |
pubmed-author:AsahinaYasuhiroY,
pubmed-author:EnomotoNobuyukiN,
pubmed-author:HondaMasaoM,
pubmed-author:ItoKiyoakiK,
pubmed-author:IzumiNamikiN,
pubmed-author:KanekoShuichiS,
pubmed-author:KurosakiMasayukiM,
pubmed-author:MaekawaShinyaS,
pubmed-author:MasakiNaohikoN,
pubmed-author:MatsuuraKentaroK,
pubmed-author:MizokamiMasashiM,
pubmed-author:NakagawaMinaM,
pubmed-author:NishidaNaoN,
pubmed-author:SakaiAkitoA,
pubmed-author:SakamotoMinoruM,
pubmed-author:SakamotoNaoyaN,
pubmed-author:SugauchiFuminakaF,
pubmed-author:SugiyamaMasayaM,
pubmed-author:TanakaYasuhitoY,
pubmed-author:TokunagaKatsushiK,
pubmed-author:WatanabeMamoruM
|
|
pubmed:copyrightInfo |
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
439-48
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21129805-Aged,
pubmed-meshheading:21129805-Alleles,
pubmed-meshheading:21129805-Antiviral Agents,
pubmed-meshheading:21129805-Data Mining,
pubmed-meshheading:21129805-Decision Trees,
pubmed-meshheading:21129805-Drug Resistance, Viral,
pubmed-meshheading:21129805-Female,
pubmed-meshheading:21129805-Genes, Viral,
pubmed-meshheading:21129805-Genotype,
pubmed-meshheading:21129805-Hepacivirus,
pubmed-meshheading:21129805-Hepatitis C, Chronic,
pubmed-meshheading:21129805-Humans,
pubmed-meshheading:21129805-Interferon Type I,
pubmed-meshheading:21129805-Interleukins,
pubmed-meshheading:21129805-Japan,
pubmed-meshheading:21129805-Logistic Models,
pubmed-meshheading:21129805-Male,
pubmed-meshheading:21129805-Middle Aged,
pubmed-meshheading:21129805-Models, Biological,
pubmed-meshheading:21129805-Mutation,
pubmed-meshheading:21129805-Polymorphism, Single Nucleotide,
pubmed-meshheading:21129805-Prognosis,
pubmed-meshheading:21129805-RNA, Viral,
pubmed-meshheading:21129805-Recombinant Proteins,
pubmed-meshheading:21129805-Retrospective Studies,
pubmed-meshheading:21129805-Ribavirin,
pubmed-meshheading:21129805-Treatment Outcome,
pubmed-meshheading:21129805-Viral Core Proteins,
pubmed-meshheading:21129805-Viral Load
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
|
|
pubmed:affiliation |
Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino-shi, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Validation Studies
|
